Press Releases

In This Section

Filter Releases
 
Press Releases
Date Title and Summary View
May 10, 2018
VANCOUVER, B.C., May 10, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases ("Novelion" or the "Company"), today reported financial results for the first quarter ended March 31, 2018 and provided an overview ...
Mar 31, 2018
VANCOUVER, British Columbia, March 31, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today recognizes World Lipodystrophy Day. Chief Operating Officer Jeff Hackman said, "We are honored to join together with the ...
Mar 15, 2018
Novelion reports 2017 total net revenues of $138.4 million, in line with previously stated guidancePlans underway to address capital structure and advance metreleptin development program VANCOUVER, British Columbia, March 15, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing an...
Mar 15, 2018
VANCOUVER, British Columbia, March 15, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, today announced that subsidiary Aegerion Pharmaceuticals, Inc. has entered into a new secured financing facility wi...
Feb 28, 2018
VANCOUVER, British Columbia, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced its alliance with the National Organization for Rare Disorders (NORD), Rare Diseases Europe (EURORDIS), Canadi...
Jan 30, 2018
VANCOUVER, British Columbia, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, today announced that a U.S. District Court judge has sentenced Novelion subsidiary Aegerion Pharmaceuticals. The sen...
Jan 24, 2018
VANCOUVER, British Columbia, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, today announced significant cost reduction plans as it continues to manage its cash resources and the effects of the...
Dec 4, 2017
VANCOUVER, British Columbia, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, today announced the appointment of Michael Price as senior vice president and chief financial officer (CFO), effecti...
Nov 21, 2017
VANCOUVER, British Columbia, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, today announced that District Judge William Young rejected Aegerion Pharmaceuticals' amended criminal plea agreement...
Nov 9, 2017
Company Reiterates FY 2017 Guidance for Total Net Revenues of $135-$145 millionCompany Announces Leadership Change and Search for Chief Executive Officer VANCOUVER, British Columbia, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing and commercializing innovative new t...
Oct 31, 2017
VANCOUVER, British Columbia, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, today announced the appointment of Jeffrey Hackman as Executive Vice President and Chief Operating Officer, effectiv...
Oct 12, 2017
VANCOUVER, British Columbia, Oct. 12, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, today announced the appointment of Murray Stewart, M.D. as Executive Vice President, Head of R&D, effective November...
Sep 24, 2017
VANCOUVER, British Columbia, and CAMBRIDGE, Mass., Sept. 24, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today its observance of The FH Foundation's annual Familial Hypercholesterolemia (FH) Awarene...
Sep 15, 2017
VANCOUVER, British Columbia and CAMBRIDGE, Mass., Sept. 15, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the presentation of two separate studies by independent researchers at the 10th Internat...
Sep 11, 2017
VANCOUVER, British Columbia, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment of Suzanne Bruhn, Ph.D. to its board of directors, effective October 1, 2017. Jason Arye...
Aug 8, 2017
MYALEPT® Total Net Revenues Increase 28% Over Prior Quarter, Excluding One-Time AdjustmentsGlobal Expansion Plans for Metreleptin Opportunity UnderwayCompany Updates Guidance for FY 2017 Total Net RevenuesConference call to be held today at 8:30 a.m. ET VANCOUVER, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a...
Aug 2, 2017
VANCOUVER, British Columbia, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment of Mark DiPaolo to its board of directors, effective immediately. Jason Aryeh, chairman o...
Jul 28, 2017
VANCOUVER, British Columbia, July 28, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that management will host a conference call and audio webcast on Tuesday, August 8, 2017 at 8:30 a.m. Eastern ...
Jun 26, 2017
VANCOUVER, British Columbia, June 26, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that it has been added to the Russell 3000® and Russell Microcap® as part of the FTSE's annual recon...
Jun 12, 2017
VANCOUVER, British Columbia and CAMBRIDGE, Mass., June 12, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the presentation of data by researchers at the American Diabetes Association Scientific S...
Jun 1, 2017
VANCOUVER, British Columbia and CAMBRIDGE, Mass., June 01, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment of John J. Orloff, M.D. to its board of directors, effective as of July 1...
May 9, 2017
Global Expansion Plans for Metreleptin Opportunity to be Announced this Summer  Defined Clinical Development Plan for Zuretinol Following Positive FDA MeetingCompany Reiterates FY 2017 Total Net Revenues Guidance Between $155 and $165 millionConference call to be held today at 8:30 a.m. ET VANCOUVER, British Columbia, May 09, 2017 (GLOBE NEWSWI...
May 5, 2017
VANCOUVER, British Columbia and CAMBRIDGE, Mass., May 05, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the presentation of data by academic researchers at the American Association of...
May 3, 2017
VANCOUVER, British Columbia, May 03, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that management will host a conference call and audio webcast on Tuesday, May 9, 2017 at 8:30 a.m. Eastern Time...
Apr 25, 2017
VANCOUVER, British Columbia, April 25, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today that the company will participate in the Bloom Burton & Co. Healthcare Investor Conference in Tor...
Apr 19, 2017
VANCOUVER, British Columbia, April 19, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that, as part of its cost rationalization process, the Company's request to voluntarily delist it...
Apr 4, 2017
VANCOUVER, British Columbia & CAMBRIDGE, Mass., April 04, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the presentation of four separate data presentations by academic researchers in...
Mar 31, 2017
VANCOUVER, British Columbia, March 31, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment of Mark Corrigan, M.D. to its board of directors, effective immediately. Dr. Corri...
Mar 31, 2017
VANCOUVER, British Columbia, March 31, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced its observance of World Lipodystrophy Day. Chief Executive Officer Mary Szela said, "We sup...
Mar 30, 2017
VANCOUVER, British Columbia and CAMBRIDGE, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, and its subsidiary today announced the presentation of data by academic researchers at ENDO 2...
Mar 15, 2017
Company Reiterates FY 2017 Total Net Product Sales Expected to be Between $155 and $165 million Global Expansion Plans for Metreleptin Opportunity Underway VANCOUVER, British Columbia, March 15, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of...
Mar 13, 2017
VANCOUVER, British Columbia, March 13, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that management will host a conference call and audio webcast on Wednesday, March 15, 2017 at 8:30...
Mar 8, 2017
VANCOUVER, British Columbia and CAMBRIDGE, Mass., March 08, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today that the company will participate in the 29th Annual ROTH Conference. Chief ...
Mar 7, 2017
VANCOUVER, British Columbia & CAMBRIDGE, Mass., March 07, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that the United States Patent Trial and Appeal Board (PTAB) issued a written de...
Mar 1, 2017
VANCOUVER, British Columbia and CAMBRIDGE, Mass., March 01, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today that the company will participate in the Cowen and Company 37th Annual Healt...
Feb 28, 2017
VANCOUVER, British Columbia and CAMBRIDGE, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced today its alliance with the National Organization for Rare Disorders (NORD), R...
Jan 23, 2017
VANCOUVER, British Columbia, Jan. 23, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applic...
Jan 9, 2017
- Company Reports Preliminary Total Net Product Sales Expected to be Between $150 million and $152 million, Exceeding High End of Prior Guidance - Global Expansion Plans for Metreleptin Opportunity Underway VANCOUVER, British Columbia, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical...
Jan 4, 2017
VANCOUVER, B.C., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Novelion Therapeutics, Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today that the company will participate in the 35th Annual J.P. Morgan Healthcare Conference in San Francisco. Chief Executive ...
Dec 22, 2016
- If approved, metreleptin would be the first medication available in the EU to treat generalized and partial lipodystrophies - More than 100 patients are currently treated with metreleptin via a compassionate use program in Europe VANCOUVER, B.C., Dec. 22, 2016 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biop...
Dec 16, 2016
VANCOUVER, British Columbia, Dec. 16, 2016 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases (the "Company"), today completed a one-for-five (1:5) reverse split of its common stock (the "Consolidation"). The C...
Dec 16, 2016
VANCOUVER, British Columbia, Dec. 16, 2016 (GLOBE NEWSWIRE) -- Novelion Therapeutics (NASDAQ:NVLN) (TSX:NVLN), today announced that subsidiary Aegerion Pharmaceuticals completed the first commercial shipment of JUXTAPID® (lomitapide) to a patient in Japan. In September 2016, JUXTAPID was approved by Japan's Ministry of Health, Labor & Welfar...
Dec 5, 2016
VANCOUVER, British Columbia, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases (the "Company"), today announced that on December 3, 2016, Aegerion Pharmaceuticals, an indirect, wholly-owned subsi...
Dec 5, 2016
-- Transaction provides new royalty and potential milestone revenues, opportunity to reduce cost structure, and continuity of patient access to lomitapide - CAMBRIDGE, Mass., Dec. 05, 2016 (GLOBE NEWSWIRE) -- Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), today announced that its subsidiary, Aegerion Pharmaceuticals, Inc., has entered...

= add release to Briefcase